Table 3 Meta-analysis of the studies reporting the association between over-expressed SNHG16 and clinicopathological parameters
Clinicopathological parameters | Studies | Patients | Model | OR (95% CI) | P value | Heterogeneity | ||
|---|---|---|---|---|---|---|---|---|
I2(%) | χ2 | P-value | ||||||
Smoking (yes vs no) | 4 | 296 | Fixed | 1.175 (0.744–1.854) | 0.489 | 8.3 | 3.27 | 0.351 |
Sex (male vs female) | 12 | 1051 | Fixed | 1.286 (0.766–1.277) | 0.932 | 0.0 | 5.05 | 0.929 |
Distant metastasis (yes vs no) | 5 | 362 | Random | 3.033 (0.991–9.281) | 0.052 | 78.8 | 18.89 | 0.001 |
Lymph node metastasis (yes vs no) | 9 | 777 | Random | 1.923 (0.781–4.735) | 0.155 | 83.8 | 49.38 | 0.000 |
Tumor number (multiple vs single) | 2 | 378 | Fixed | 0.829 (0.531–1.293) | 0.409 | 0.0 | 0.01 | 0.910 |
Tumor size (≥5 cm vs<5 cm) | 5 | 373 | Fixed | 3.357 (2.173–5.185) | 0 | 0.0 | 1.57 | 0.813 |
TNM stage (III/IV vs I/II) | 8 | 591 | Random | 2.930 (1.522–5.640) | 0.001 | 64.2 | 19.58 | 0.007 |
Histological grade (poorly vs well/moderately) | 3 | 187 | Fixed | 3.943 (1.955–7.952) | 0 | 13.8 | 2.32 | 0.313 |